Lester, Jason F.

Tracking the Evolution of Non–Small-Cell Lung Cancer

Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 2,349

Abiraterone for prostate cancer not previously treated with hormone therapy

James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 1,801

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 1,298

Lung adenocarcinoma promotion by air pollutants

Hill, W., Lim, E. L., Weeden, C. E., Lee, C., Augustine, M., Chen, K., Kuan, F.-C., Marongiu, F., Evans, E. J., Moore, D. A., et al. (2023) · Nature

Air Quality and Health ImpactsCarcinogens and Genotoxicity Assessment

Cited by 808

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 592

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

Abbosh, C., Frankell, A. M., Harrison, T., Kisistok, J., Garnett, A., Johnson, L., Veeriah, S., Moreau, M., Chesh, A., Chaunzwa, T. L., et al. (2023) · Nature

Cancer Genomics and DiagnosticsLung Cancer Diagnosis and Treatment

Cited by 382

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK

Califano, R., Tariq, N., Compton, S., Fitzgerald, D. A., Harwood, C. A., Lal, R., Lester, J., McPhelim, J., Mulatero, C., Subramanian, S., et al. (2015) · Drugs

Lung Cancer Treatments and MutationsChemotherapy-related skin toxicity

Cited by 152

Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial

Hoskin, P. J., Hopkins, K., Misra, V., Holt, T., McMenemin, R., Dubois, D., McKinna, F., Foran, B., Madhavan, K., MacGregor, C., et al. (2019) · JAMA

Management of metastatic bone diseaseSpinal Fractures and Fixation Techniques

Cited by 120

PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial

Fennell, D., Ottensmeier, C., Califano, R., Hanna, G., Ewings, S., Hill, K., Wilding, S., Danson, S., Nye, M., Steele, N., et al. (2021) · Journal of Thoracic Oncology

Occupational and environmental lung diseasesIntraperitoneal and Appendiceal Malignancies

Cited by 34

Prostaglandin E2-mediated adenosinergic effects on CD14+cells: Self-amplifying immunosuppression in cancer

Al-Taei, S., Salimu, J., Spary, L. K., Clayton, A., Lester, J. F., & Tabi, Z. (2017) · OncoImmunology

Adenosine and Purinergic SignalingBiochemical and Molecular Research

Cited by 17